Insider Selling: Monopar Therapeutics (NASDAQ:MNPR) Director Sells $214,755.70 in Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Raymond Anderson sold 3,142 shares of the stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $68.35, for a total value of $214,755.70. Following the transaction, the director owned 5,373 shares in the company, valued at $367,244.55. This represents a 36.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raymond Anderson also recently made the following trade(s):

• On Tuesday, August 25th, Raymond Anderson sold 3,142 shares of Monopar Therapeutics stock. The stock was sold at an average price of $111.77, for a total value of $351,181.34.

Monopar Therapeutics Stock Performance

MNPR stock opened at $71.42 on Friday. The business has a 50 day moving average price of $86.88 and a two-hundred day moving average price of $77.39. Monopar Therapeutics Inc. has a twelve month low of $50.07 and a twelve month high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last issued its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.02. Equities research analysts forecast that Monopar Therapeutics Inc. will post -2.98 EPS for the current fiscal year.

Institutional Investors Weigh In On Monopar Therapeutics

Several large investors have recently added to or reduced their stakes in MNPR. Siren L.L.C. increased its position in shares of Monopar Therapeutics by 27.2% during the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after acquiring an additional 57,820 shares in the last quarter. ADAR1 Capital Management LLC lifted its stake in shares of Monopar Therapeutics by 13.0% in the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after acquiring an additional 30,370 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Monopar Therapeutics by 21.2% during the first quarter. Bank of New York Mellon Corp now owns 78,618 shares of the company’s stock worth $4,307,000 after buying an additional 13,761 shares in the last quarter. Walleye Capital LLC acquired a new stake in shares of Monopar Therapeutics in the first quarter worth $3,458,000. Finally, Bank of America Corp DE boosted its position in shares of Monopar Therapeutics by 838.2% in the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after purchasing an additional 53,336 shares during the last quarter. Institutional investors and hedge funds own 1.83% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on MNPR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Thursday, October 15th. BTIG Research boosted their price objective on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Morgan Stanley restated an “overweight” rating and set a $130.00 price target on shares of Monopar Therapeutics in a report on Monday, August 17th. Wall Street Zen cut shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 10th. Finally, Cantor Fitzgerald cut shares of Monopar Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price objective for the stock from $109.00 to $119.00 in a research note on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Monopar Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $122.00.

About Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company’s research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies.

Monopar’s pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR.